Insider Selling: Vaccitech plc (NASDAQ:VACC) CEO Sells $36,300.00 in Stock

Posted by on Apr 1st, 2023

Vaccitech plc (NASDAQ:VACC – Get Rating) CEO William Enright sold 15,000 shares of the firm’s stock in a transaction dated Monday, March 27th. The stock was sold at an average price of $2.42, for a total transaction of $36,300.00. Following the completion of the transaction, the chief executive officer now directly owns 728,454 shares in the company, valued at approximately $1,762,858.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vaccitech Stock Down 2.6 %

Vaccitech stock opened at $2.24 on Friday. The stock has a market cap of $83.55 million, a P/E ratio of 14.93 and a beta of 0.21. Vaccitech plc has a 12 month low of $2.02 and a 12 month high of $7.45. The company’s fifty day simple moving average is $2.85 and its 200-day simple moving average is $2.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright cut their price target on Vaccitech from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, March 27th. Barclays dropped their price target on Vaccitech from $23.00 to $7.00 in a report on Sunday, March 26th.

Institutional Investors Weigh In On Vaccitech

A number of large investors have recently bought and sold shares of VACC. M&G Investment Management Ltd. boosted its holdings in Vaccitech by 377.4% during the third quarter. M&G Investment Management Ltd. now owns 5,197,349 shares of the company’s stock valued at $15,592,000 after acquiring an additional 4,108,752 shares during the period. Alphabet Inc. acquired a new position in Vaccitech in the third quarter worth about $4,844,000. Baird Financial Group Inc. acquired a new position in Vaccitech in the fourth quarter worth about $217,000. Finally, Millennium Management LLC increased its holdings in shares of Vaccitech by 32.8% during the fourth quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock worth $97,000 after buying an additional 9,967 shares in the last quarter. 27.07% of the stock is currently owned by institutional investors.

About Vaccitech

(Get Rating)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.

Read More

Insider Buying and Selling by Quarter for Vaccitech (NASDAQ:VACC)

Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.